Patents for A61P 35 - Antineoplastic agents (221,099)
03/2011
03/01/2011US7897384 Chondrocyte therapeutic delivery system
03/01/2011US7897351 Peptides and antibodies to MUC 1 proteins
03/01/2011US7897346 Polyamide nucleic acid derivatives and agents, and processes for preparing them
03/01/2011US7897152 Viral chemokine-antigen fusion proteins
03/01/2011CA2677068A1 Nucleic acid compounds for inhibiting gene expression and uses thereof
03/01/2011CA2469154C Cytotoxic protein and utilization thereof
03/01/2011CA2411660C Enzyme-cleavable prodrug compounds
03/01/2011CA2396590C 2-amino-nicotinamide derivatives and their use as vegf-receptor tyrosine kinase inhibitors
03/01/2011CA2368618C Method of enhancing the efficacy of anti-tumor agents
03/01/2011CA2348488C Novel agents and methods for treatment and diagnosis of ocular disorders
03/01/2011CA2339331C Expression and export of angiogenesis inhibitors as immunofusins
03/01/2011CA2323525C Therapeutic and diagnostic applications based on the role of the cxcr-4 gene in tumorigenesis
02/2011
02/24/2011WO2011022694A2 Furanopyrimidine cannabinoid compounds and related methods of use
02/24/2011WO2011022692A2 Furanopyridine cannabinoid compounds and related methods of use
02/24/2011WO2011022679A2 Benzofuran cannabinoid compounds and related methods of use
02/24/2011WO2011022509A2 Substituted benzoazepines as toll-like receptor modulators
02/24/2011WO2011022508A2 Substituted benzoazepines as toll-like receptor modulators
02/24/2011WO2011022489A2 (bis) urea and (bis) thiourea compounds as epigenic modulators of lysine-specific demethylase 1 and methods of treating disorders
02/24/2011WO2011022264A1 Anti-angiogenesis therapy for the treatment of previously treated breast cancer
02/24/2011WO2011022056A2 PEPTIDE MODULATORS OF THE δPKC INTERACTION WITH THE D SUBUNIT OF F1FO ATP SYNTHASE/ATPASE AND USES THEREOF
02/24/2011WO2011021864A2 Novel compound for complementing anticancer drugs, a production method for the same, a composition for complementing anticancer drugs comprising the same, and a method for reducing resistance to anticancer drugs using the same
02/24/2011WO2011021678A1 Fused heterocyclic compound
02/24/2011WO2011021597A1 Quinoline derivative-containing pharmaceutical composition
02/24/2011WO2011021524A1 Peptides inducing adhesive property of lactic acid bacterium and use of same
02/24/2011WO2011021503A1 Pharmaceutical composition containing transiently surviving ctl
02/24/2011WO2011021397A1 Colchicine derivatives
02/24/2011WO2011021386A1 Cstf2 for target genes of lung cancer therapy and diagnosis
02/24/2011WO2011021381A1 Pharmaceutical composition containing anti-hb-egf antibody as active ingredient
02/24/2011WO2011021212A1 Methods of treating drug resistant and other tumors with 6,7-dialkoxy quinazoline derivatives
02/24/2011WO2011021209A1 Histone deacetylase inhibitors
02/24/2011WO2011021038A1 Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors
02/24/2011WO2011020861A1 Heterocyclic oxime compounds
02/24/2011WO2011020615A1 Novel fxr (nr1h4 ) binding and activity modulating compounds
02/24/2011WO2011020294A1 Magnetic nanoparticles having novel core-shell structure and ph responsiveness, and use thereof
02/24/2011WO2011020288A1 Substituted hydrazide compounds and application thereof
02/24/2011WO2011001122A3 Pyrazole derivatives, preparation thereof, and therapeutic use thereof
02/24/2011WO2011001113A3 Novel 1,2,3,4-tetrahydro-pyrimido(1,2-a)pyrimidin-6-one derivatives, preparation thereof, and pharmaceutical use thereof
02/24/2011WO2010149944A8 Indolyl-substituted pyrazino-quinolines and their use for the treatment of cancer
02/24/2011WO2010125462A4 Pentamidine combinations for treating cancer
02/24/2011WO2010121675A3 Thiazolyl-benzimidazoles
02/24/2011WO2010121164A3 1,4-benzodiazepinone compounds and their use in treating cancer
02/24/2011WO2010120942A3 Histone modification patterns for clinical diagnosis and prognosis of cancer
02/24/2011WO2010117992A3 Coupled identification and treatment of cancer
02/24/2011WO2010107909A3 Methods and compositions for the detection of cancer
02/24/2011WO2010104749A3 Antigen presenting cell targeted cancer vaccines
02/24/2011WO2010104588A3 Compositions and methods for characterizing and treating neoplasia
02/24/2011WO2010096719A3 Anticancer and antimicrobial compounds from antarctic extremophilic microorganisms
02/24/2011WO2010095879A3 Sirna to be bound to transcripts of apoptosis-related genes, and compositions for treating cancer using same
02/24/2011WO2010080769A4 Chemotherapeutic methods and compositions
02/24/2011WO2010077663A3 Substituted tetracyclic 1h-indeno (1,2-b) pyridine-2 (5h)-one analogs thereof and uses thereof
02/24/2011WO2010039997A3 Hematopoietic protection against chemotherapeutic compounds using selective cyclin-dependent kinase 4/6 inhibitors
02/24/2011WO2010028780A3 Preparation and uses of guanidinium-modified porphyrins and phthalocyanines
02/24/2011US20110047631 Heat shock protein deficiencies as model systems for brain pathology and cancer
02/24/2011US20110047103 Anti-angiogenesis therapy for the treatment of previously treated breast cancer
02/24/2011US20110046606 Catheter injectable depot compositions and uses thereof
02/24/2011US20110046237 Compounds with activity at estrogen receptors
02/24/2011US20110046235 Products comprising, and uses of, decarboxylated phenolic acids derived from chlorogenic acids of coffee
02/24/2011US20110046234 Retinaldehyde in the Treatment of Obesity, Diabetes and Other Conditions
02/24/2011US20110046233 Gossypol derivatives, production method thereof and uses of same
02/24/2011US20110046211 Combination therapy of hedgehog inhibitors, radiation and chemotherapeutic agents
02/24/2011US20110046210 Substituted thiopenecarboxamides as ikk-beta serine-, threonine-protein kinase inhibitors
02/24/2011US20110046209 RNA-Induced Translational Silencing and Cellular Apoptosis
02/24/2011US20110046204 Human Zip1, Zinc and Citrate for Prostate Cancer Screening
02/24/2011US20110046197 3-aminocarbazole compounds, pharmaceutical composition containing the same and method for the preparation thereof
02/24/2011US20110046190 Combinations comprising a selective cyclooxygenase-2 inhibitor
02/24/2011US20110046189 Heteroaryl-substituted bicyclic smac mimetics and the uses thereof
02/24/2011US20110046183 Crystal of benzimidazole compound
02/24/2011US20110046182 Efficient aspirin prodrugs
02/24/2011US20110046176 Furanopyridine cannabinoid compounds and related methods of use
02/24/2011US20110046175 Benzofuran cannabinoid compounds and related methods of use
02/24/2011US20110046170 Novel pyrimidine-pyridine derivatives
02/24/2011US20110046169 Fused heterocyclic derivatives and use thereof
02/24/2011US20110046168 Methods of treating diseases using quinazoline derivatives and pharmaceutical compositions containing them
02/24/2011US20110046167 Acyclic amine inhibitors of 5-methytioadenosine phosphorylase and nucleosidase
02/24/2011US20110046165 Certain chemical entitles, compositions and methods
02/24/2011US20110046163 Furanopyrimidine cannabinoid compounds and related methods of use
02/24/2011US20110046157 Substituted hydroxamic acids and uses thereof
02/24/2011US20110046155 Hydrobenzamide derivatives as inhibitors of hsp90
02/24/2011US20110046154 Use of aminopeptidase inhibitors or azaindole compounds for preventing or treating cancerous metastases from epithelial origin
02/24/2011US20110046147 17beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of hormone-related diseases
02/24/2011US20110046144 Imidazopyrazinol derivatives for the treatment of cancers
02/24/2011US20110046143 Disubstituted phthalazine hedgehog pathway antagonists
02/24/2011US20110046131 Purines as pkc-theta inhibitors
02/24/2011US20110046127 Imidazopyridazines for Use as Protein Kinase Inhibitors
02/24/2011US20110046122 3-amino-5-phenyl-5,6-dihydro-2h-[1,4]oxazines
02/24/2011US20110046113 Amine compound and use thereof
02/24/2011US20110046111 Quinazoline linked pyrrolo[2,1-c][1, 4]benzodiazepine hybrids as potential anticancer agents and process for the preparation thereof
02/24/2011US20110046109 2,4,8-trisubstituted-8h-pyrido[2,3-d]pyrimidin-7-one compounds and compositions for use in therapy
02/24/2011US20110046108 Pyrimidine derivatives
02/24/2011US20110046100 Texaphyrin solutions and pharmaceutical formulations
02/24/2011US20110046098 Progesterone antagonists such as cdb-4124 in the treatment of endometriosis, uterine fibroids, dysmenorrhea, breast cancer, etc.
02/24/2011US20110046097 Substituted indolin-2-one derivatives and their use as p38 mitogen-activated kinase inhibitors
02/24/2011US20110046093 Pyrimidine derivatives as protein kinase inhibitors
02/24/2011US20110046086 Composition Comprising Polysaccharide Extracted from Panax Ginseng Preventing and Treating Liver Diseases
02/24/2011US20110046083 Activators of pyruvate kinase m2 and methods of treating disease
02/24/2011US20110046078 Methods and compositions for treating diseases and disorders associated with siglec-8
02/24/2011US20110046071 GLP-1 Receptor Agonists And Related Active Pharmaceutical Ingredients For Treatment Of Cancer
02/24/2011US20110046070 Gene expression inhibitor selective for matrix metalloproteinase-9 gene
02/24/2011US20110046069 Uses of Modified ELR-CXC Chemokine G31P
02/24/2011US20110046068 Compound, Use and Method